Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer

Nature Reviews Cancer

Volumn 12, Issue 5, 2012, Pages 372-373

  Yu, Ke Da ^a,b   Shao, Zhi Ming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; REACTIVE OXYGEN METABOLITE;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA DAMAGE; FEMALE; HUMANS;

EID: 84860208603     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3181-c1     Document Type: Letter

References (15)

1. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Rev. Cancer 12, 68-78 (2012).
2. Molyneux, G. & Smalley, M. J. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling. J. Mammary Gland Biol. Neoplasia 16, 51-55 (2011).
3. Yager, J. D. & Davidson, N. E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282 (2006).
4. King, T. A. et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann. Surg. Oncol. 14, 2510-2518 (2007). (Pubitemid 47389559)
5. Mulligan, A. M. et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 13, R110 (2011).
6. Hosey, A. M. et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J. Natl Cancer Inst. 99, 1683-1694 (2007). (Pubitemid 351767217)
7. Gorski, J. J. et al. BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res. Treat 122, 721-731 (2010).
8. Birgisdottir, V. et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 8, R38 (2006).
9. Pang, D. et al. Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese. Med. Oncol. 11 Nov 2011 (doi:10.1007/s12032-011-0100-0).
10. Foulkes, W. D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95, 1482-1485 (2003). (Pubitemid 37279334)
11. Stefansson, O. A. et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 6, 638-649 (2011).
12. Jin, W. et al. Estrogen receptor (ER) β or p53 attenuates ERα-mediated transcriptional activation on the BRCA2 promoter. J. Biol. Chem. 283, 29671-29680 (2008).
13. Lee, E. H. et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res. Treat 122, 11-25 (2010).
14. Goodwin, P. J. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J. Clin. Oncol. 30, 19-26 (2012).
15. Bolton, K. L. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307, 382-390 (2012).